WallStreetZenWallStreetZen

NASDAQ: BRVE
Braveheart Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BRVE

Based on 3 analysts offering 12 month price targets for Braveheart Bio Inc

Min Forecast
$40.00+93.99%
Avg Forecast
$44.33+115%
Max Forecast
$48.00+132.78%

Should I buy or sell BRVE stock?

Based on 4 analysts offering ratings for Braveheart Bio Inc.

Strong Buy
Strong Buy
4 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BRVE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BRVE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their BRVE stock forecasts and price targets.

BRVE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-31

1 of 1

Forecast return on equity

Is BRVE forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is BRVE forecast to generate an efficient return on assets?

Company
-126.96%
Industry
-4.33%
BRVE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BRVE earnings per share forecast

What is BRVE's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.71
Avg 2 year Forecast
-$1.66
Avg 3 year Forecast
-$1.79

BRVE revenue forecast

What is BRVE's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

BRVE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BRVE$20.62$44.33+115.00%Strong Buy
ZYME$26.52$39.14+47.60%Strong Buy
FTRE$19.89$22.00+10.61%Strong Buy
VIR$10.66$24.00+125.14%Strong Buy
LKFT$29.38$35.50+20.83%Buy
View Top Biotech Stocks

Braveheart Bio Stock Forecast FAQ

Is Braveheart Bio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: BRVE) stock is to Strong Buy BRVE stock.

Out of 4 analysts, 4 (100%) are recommending BRVE as a Strong Buy, 0 (0%) are recommending BRVE as a Buy, 0 (0%) are recommending BRVE as a Hold, 0 (0%) are recommending BRVE as a Sell, and 0 (0%) are recommending BRVE as a Strong Sell.

If you're new to stock investing, here's how to buy Braveheart Bio stock.

What is BRVE's earnings growth forecast for 2026-2028?

(NASDAQ: BRVE) Braveheart Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.61%.

Braveheart Bio's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast BRVE's earnings for 2026 to be -$154,065,680, with the lowest BRVE earnings forecast at -$259,420,277, and the highest BRVE earnings forecast at -$79,414,371. On average, 7 Wall Street analysts forecast BRVE's earnings for 2027 to be -$149,149,552, with the lowest BRVE earnings forecast at -$206,477,364, and the highest BRVE earnings forecast at -$103,995,009.

In 2028, BRVE is forecast to generate -$161,178,758 in earnings, with the lowest earnings forecast at -$211,771,655 and the highest earnings forecast at -$113,449,101.

What is BRVE's revenue growth forecast for 2026-2028?

(NASDAQ: BRVE) Braveheart Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 43.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.28%.

Braveheart Bio's revenue in 2026 is N/A.On average, 7 Wall Street analysts forecast BRVE's revenue for 2026 to be $0, with the lowest BRVE revenue forecast at $0, and the highest BRVE revenue forecast at $0. On average, 7 Wall Street analysts forecast BRVE's revenue for 2027 to be $0, with the lowest BRVE revenue forecast at $0, and the highest BRVE revenue forecast at $0.

In 2028, BRVE is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BRVE's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: BRVE) forecast ROA is -126.96%, which is lower than the forecast US Biotechnology industry average of -4.33%.

What is BRVE's Price Target?

According to 3 Wall Street analysts that have issued a 1 year BRVE price target, the average BRVE price target is $44.33, with the highest BRVE stock price forecast at $48.00 and the lowest BRVE stock price forecast at $40.00.

On average, Wall Street analysts predict that Braveheart Bio's share price could reach $44.33 by Aug 31, 2027. The average Braveheart Bio stock price prediction forecasts a potential upside of 115% from the current BRVE share price of $20.62.

What is BRVE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BRVE) Braveheart Bio's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that BRVE's EPS will be -$1.71 for 2026, with the lowest EPS forecast at -$2.88, and the highest EPS forecast at -$0.88. On average, analysts forecast that BRVE's EPS will be -$1.66 for 2027, with the lowest EPS forecast at -$2.29, and the highest EPS forecast at -$1.16. In 2028, BRVE's EPS is forecast to hit -$1.79 (min: -$2.35, max: -$1.26).

What is BRVE's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: BRVE) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.